NCT04945772: An overdue trial by Nanoscope Therapeutics Inc.
This trial is overdue. It was due to report 6 months ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
| Full entry on ClinicalTrials.gov | NCT04945772 |
|---|---|
| Title | A Phase 2b Randomized, Double-Masked, Sham-Controlled, Study to Evaluate the Efficacy and Safety of Intravitreal Injection of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE] |
| Results Status | Overdue |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 13, 2021 |
| Completion date | Feb. 27, 2023 |
| Required reporting date | Feb. 27, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 25, 2026 |
| Days late | 179 |